Macugen (Pegaptanib Sodium) Alone, Versus Macugen in Combination With PDT (Photodynamic Therapy) With Visudyne (Verteporfin) in Patients With Age-Related Macular Degeneration (AMD)

Phase 4TerminatedNCT00134667

Eyetech Pharmaceuticals360 enrolled

Overview

The purpose of the trial is to compare whether Macugen (pegaptanib sodium) in combination with PDT with Visudyne (verteporfin) is safe and effective in slowing down the leakage of fluid within the eye and thereby stabilizing or improving vision when compared to Macugen alone. Patients must be recently diagnosed with predominantly classic wet AMD and must be eligible for PDT.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

360

Conditions

Age-Related Macular Degeneration

Interventions

Photodynamic Therapy (PDT) with Visudyne (verteporfin)DRUG

Macugen (pegaptanib sodium)DRUG

Eligibility

Sex: ALLMin age: 50 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Subjects of either gender; aged 50 years or greater. * Subfoveal choroidal neovascularization (CNV) due to AMD with predominantly classic lesion composition * Best corrected visual acuity in the study eye between 20/40 and 20/200 Exclusion Criteria: * Any prior PDT with Visudyne to the study eye * Any previous AMD thermal laser therapy to the study eye

Locations (1)

Retina Centers, P.C., Northwest Location

Tucson, Arizona, United States

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.